<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Neurotech International Ltd — News on 6ix</title>
<link>https://6ix.com/company/neurotech-international-ltd</link>
<description>Latest news and press releases for Neurotech International Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 17 Mar 2026 02:53:05 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/neurotech-international-ltd" rel="self" type="application/rss+xml" />
<item>
<title>NTI initiates First Clinical Site for Phase 3 ASD Trial</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/nti-initiates-first-clinical-site-for-phase-3-asd-trial</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/nti-initiates-first-clinical-site-for-phase-3-asd-trial</guid>
<pubDate>Tue, 17 Mar 2026 02:53:05 GMT</pubDate>
<description>NTI initiates First Clinical Site for Phase 3 ASD Trial</description>
</item>
<item>
<title>Appendix 4D & Half Year Report</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/appendix-4d-and-half-year-report-80</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/appendix-4d-and-half-year-report-80</guid>
<pubDate>Thu, 26 Feb 2026 12:36:03 GMT</pubDate>
<description>Appendix 4D & Half Year Report</description>
</item>
<item>
<title>Positive 90-day GLP toxicology study results in non-rodents</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/positive-90-day-glp-toxicology-study-results-in-non-rodents</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/positive-90-day-glp-toxicology-study-results-in-non-rodents</guid>
<pubDate>Mon, 23 Feb 2026 04:06:06 GMT</pubDate>
<description>Positive 90-day GLP toxicology study results in non-rodents</description>
</item>
<item>
<title>Approval received for NTI164 Phase 3 Clinical Study in ASD</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/approval-received-for-nti164-phase-3-clinical-study-in-asd</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/approval-received-for-nti164-phase-3-clinical-study-in-asd</guid>
<pubDate>Mon, 02 Feb 2026 03:57:06 GMT</pubDate>
<description>Approval received for NTI164 Phase 3 Clinical Study in ASD</description>
</item>
<item>
<title>Quarterly Activities/Appendix 4C Cash Flow Report</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-150</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-150</guid>
<pubDate>Fri, 30 Jan 2026 03:17:07 GMT</pubDate>
<description>Quarterly Activities/Appendix 4C Cash Flow Report</description>
</item>
<item>
<title>Binding Commitments Received for a $4 Million Placement</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/binding-commitments-received-for-a-dollar4-million-placement</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/binding-commitments-received-for-a-dollar4-million-placement</guid>
<pubDate>Wed, 17 Dec 2025 04:22:04 GMT</pubDate>
<description>Binding Commitments Received for a $4 Million Placement</description>
</item>
<item>
<title>Trading Halt</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/trading-halt-943</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/trading-halt-943</guid>
<pubDate>Mon, 15 Dec 2025 03:35:10 GMT</pubDate>
<description>Trading Halt</description>
</item>
<item>
<title>Neurotech receives $4.73m R&D Tax Incentive Refund</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/neurotech-receives-dollar473m-randd-tax-incentive-refund</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/neurotech-receives-dollar473m-randd-tax-incentive-refund</guid>
<pubDate>Wed, 12 Nov 2025 04:13:13 GMT</pubDate>
<description>Neurotech receives $4.73m R&D Tax Incentive Refund</description>
</item>
<item>
<title>US FDA Rare Pediatric Disease Designation in Rett syndrome</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/us-fda-rare-pediatric-disease-designation-in-rett-syndrome</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/us-fda-rare-pediatric-disease-designation-in-rett-syndrome</guid>
<pubDate>Wed, 08 Oct 2025 02:44:16 GMT</pubDate>
<description>US FDA Rare Pediatric Disease Designation in Rett syndrome</description>
</item>
<item>
<title>Appendix 4E & Annual Report to shareholders</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/appendix-4e-and-annual-report-to-shareholders-28</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/appendix-4e-and-annual-report-to-shareholders-28</guid>
<pubDate>Fri, 29 Aug 2025 06:59:15 GMT</pubDate>
<description>Appendix 4E & Annual Report to shareholders</description>
</item>
<item>
<title>Positive Human PK Study Results for NTI164</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/positive-human-pk-study-results-for-nti164</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/positive-human-pk-study-results-for-nti164</guid>
<pubDate>Mon, 02 Jun 2025 03:40:10 GMT</pubDate>
<description>Positive Human PK Study Results for NTI164</description>
</item>
<item>
<title>NTI164 Preclinical Toxicology Studies Update</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/nti164-preclinical-toxicology-studies-update</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/nti164-preclinical-toxicology-studies-update</guid>
<pubDate>Mon, 05 May 2025 04:12:14 GMT</pubDate>
<description>NTI164 Preclinical Toxicology Studies Update</description>
</item>
<item>
<title>Appendix 4D and Half Year Accounts</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/appendix-4d-and-half-year-accounts-53</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/appendix-4d-and-half-year-accounts-53</guid>
<pubDate>Thu, 27 Feb 2025 13:02:10 GMT</pubDate>
<description>Appendix 4D and Half Year Accounts</description>
</item>
<item>
<title>Positive Opinion on OMPD for NTI164 in Europe</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/positive-opinion-on-ompd-for-nti164-in-europe</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/positive-opinion-on-ompd-for-nti164-in-europe</guid>
<pubDate>Thu, 27 Feb 2025 07:19:11 GMT</pubDate>
<description>Positive Opinion on OMPD for NTI164 in Europe</description>
</item>
<item>
<title>NTI Signs Development Agreement for Cannabinoid Therapies</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/nti-signs-development-agreement-for-cannabinoid-therapies</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/nti-signs-development-agreement-for-cannabinoid-therapies</guid>
<pubDate>Thu, 13 Feb 2025 04:19:12 GMT</pubDate>
<description>NTI Signs Development Agreement for Cannabinoid Therapies</description>
</item>
<item>
<title>Neurotech Receives $2.44 Million R&D Tax Incentive Refund</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/neurotech-receives-dollar244-million-randd-tax-incentive-refund</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/neurotech-receives-dollar244-million-randd-tax-incentive-refund</guid>
<pubDate>Fri, 31 Jan 2025 02:32:41 GMT</pubDate>
<description>Neurotech Receives $2.44 Million R&D Tax Incentive Refund</description>
</item>
<item>
<title>Neurotech Receives US ODD in Rett Syndrome</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/neurotech-receives-us-odd-in-rett-syndrome</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/neurotech-receives-us-odd-in-rett-syndrome</guid>
<pubDate>Tue, 26 Nov 2024 04:06:06 GMT</pubDate>
<description>Neurotech Receives US ODD in Rett Syndrome</description>
</item>
<item>
<title>NTI Receives Ethics Approval to Commence Human PK Study</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/nti-receives-ethics-approval-to-commence-human-pk-study</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/nti-receives-ethics-approval-to-commence-human-pk-study</guid>
<pubDate>Mon, 25 Nov 2024 02:32:23 GMT</pubDate>
<description>NTI Receives Ethics Approval to Commence Human PK Study</description>
</item>
<item>
<title>Positive Genomic Effects of NTI164 in PANDAS/PANS Patients</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/positive-genomic-effects-of-nti164-in-pandaspans-patients</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/positive-genomic-effects-of-nti164-in-pandaspans-patients</guid>
<pubDate>Fri, 15 Nov 2024 02:41:07 GMT</pubDate>
<description>Positive Genomic Effects of NTI164 in PANDAS/PANS Patients</description>
</item>
<item>
<title>Neurotech Appoints Dr Anthony Filippis as MD/CEO</title>
<link>https://6ix.com/company/neurotech-international-ltd/news/neurotech-appoints-dr-anthony-filippis-as-mdceo</link>
<guid isPermaLink="true">https://6ix.com/company/neurotech-international-ltd/news/neurotech-appoints-dr-anthony-filippis-as-mdceo</guid>
<pubDate>Mon, 11 Nov 2024 02:47:29 GMT</pubDate>
<description>Neurotech Appoints Dr Anthony Filippis as MD/CEO</description>
</item>
</channel>
</rss>